Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_860014d37ad2404b7e68587a97ea00bf |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-91205 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-71 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
filingDate |
2011-01-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2015-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5c72517dbf4e15a2961c7da78c3fa450 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_191f47f90a55c0fd932676e3182a884f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1702f76c84bc82adb0463849356bcd25 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ba7a4f99b1e1d77222d266d9a701f59 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9b242081832c26eb9a68d5dae6ba9d74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6581515027ba1e77afa66cb8ecfcc3df |
publicationDate |
2015-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
RU-2558931-C2 |
titleOfInvention |
Methods of predicting response of triple negative mammary gland cancer to therapy |
abstract |
FIELD: medicine. n SUBSTANCE: claimed invention provides a method for predicting a response of triple negative mammary gland cancer to therapy with an anti-tumour medication. The method includes (a) lysing tumour cells, sampled from the triple negative mammary gland cancer to obtain a cell extract; (b) determining the level of VEGFR2 expression in the cell extract; and (c) comparison of the level of VEGFR2 expression in the cell extract, obtained at stage (b), with the standard level of VEGFR2 expression. n EFFECT: presence of a low level of VEGFR2 expression predicts the response to therapy with an anti-tumour medication, where the anti-tumour medication represents a combination of bevacizumab (Avastin ® ), carboplatin and paclitaxel. n 16 cl, 14 dwg, 7 ex |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2616533-C1 |
priorityDate |
2010-01-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |